Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Videogame play and events are related to unhealthy emotion regulation in the form of low fading affect bias in autobiographical memory.

Gibbons JA, Bouldin B.

Conscious Cogn. 2019 Sep;74:102778. doi: 10.1016/j.concog.2019.102778. Epub 2019 Jul 8.

PMID:
31295657
2.

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies.

Trang M, Seroogy JD, Van Wart SA, Bhavnani SM, Kim A, Gibbons JA, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02329-18. doi: 10.1128/AAC.02329-18. Print 2019 Apr.

3.

A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics.

Gall J, Choi T, Riddle V, Van Wart S, Gibbons JA, Seroogy J.

Clin Pharmacol Drug Dev. 2019 Nov;8(8):1032-1041. doi: 10.1002/cpdd.653. Epub 2019 Jan 16.

PMID:
30650259
4.

Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.

Wang Q, Banerjee K, Vasilinin G, Marier JF, Gibbons JA.

J Clin Pharmacol. 2019 May;59(5):748-762. doi: 10.1002/jcph.1366. Epub 2018 Dec 19.

5.

A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function.

Komirenko AS, Riddle V, Gibbons JA, Van Wart S, Seroogy JD.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01128-18. doi: 10.1128/AAC.01128-18. Print 2018 Dec.

6.

Grief and Avoidant Death Attitudes Combine to Predict the Fading Affect Bias.

Gibbons JA, Lee SA, Fehr AMA, Wilson KJ, Marshall TR.

Int J Environ Res Public Health. 2018 Aug 13;15(8). pii: E1736. doi: 10.3390/ijerph15081736.

7.
8.

Amblyomma americanum (Acari: Ixodidae) Ticks Are Not Vectors of the Lyme Disease Agent, Borrelia burgdorferi (Spirocheatales: Spirochaetaceae): A Review of the Evidence.

Stromdahl EY, Nadolny RM, Hickling GJ, Hamer SA, Ogden NH, Casal C, Heck GA, Gibbons JA, Cremeans TF, Pilgard MA.

J Med Entomol. 2018 May 4;55(3):501-514. doi: 10.1093/jme/tjx250. Review.

9.

Authors' Response.

Gibbons JA, Ashworth A, Mojica AJ, Peele ME.

J Forensic Sci. 2017 Nov;62(6):1684-1686. doi: 10.1111/1556-4029.13635. No abstract available.

PMID:
29152804
10.

Antimicrobial stewardship in the treatment of skin and soft tissue infections.

Gibbons JA, Smith HL, Kumar SC, Duggins KJ, Bushman AM, Danielson JM, Yost WJ, Wadle JJ.

Am J Infect Control. 2017 Nov 1;45(11):1203-1207. doi: 10.1016/j.ajic.2017.05.013. Epub 2017 Jul 18.

PMID:
28732743
11.

The fading affect bias shows positive outcomes at the general but not the individual level of analysis in the context of social media.

Gibbons JA, Horowitz KA, Dunlap SM.

Conscious Cogn. 2017 Aug;53:47-60. doi: 10.1016/j.concog.2017.05.009. Epub 2017 Jun 13.

PMID:
28622585
12.

Localized Heat Urticaria from 95-GHz Millimeter Waves.

Gibbons JA.

Aerosp Med Hum Perform. 2017 Jun 1;88(6):586-588. doi: 10.3357/AMHP.4707.2017.

PMID:
28539148
13.

Human Electrical Muscular Incapacitation and Effects on QTc Interval.

Gibbons JA, Mojica AJ, Peele ME.

J Forensic Sci. 2017 Nov;62(6):1516-1521. doi: 10.1111/1556-4029.13490. Epub 2017 Apr 17.

PMID:
28419455
14.

A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.

Schwartzberg LS, Yardley DA, Elias AD, Patel M, LoRusso P, Burris HA, Gucalp A, Peterson AC, Blaney ME, Steinberg JL, Gibbons JA, Traina TA.

Clin Cancer Res. 2017 Aug 1;23(15):4046-4054. doi: 10.1158/1078-0432.CCR-16-2339. Epub 2017 Mar 9.

15.

Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs.

Ohtsu Y, Gibbons JA, Suzuki K, Fitzsimmons ME, Nozawa K, Arai H.

Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):611-626. doi: 10.1007/s13318-016-0374-x.

PMID:
27590197
16.

School and religious factors impact the neuroticism-grief link in adolescents.

Lee SA, Callan SM, Gibbons JA.

Death Stud. 2016 Nov-Dec;40(10):601-606. Epub 2016 Jun 22.

PMID:
27333448
17.

Testing the fading affect bias for healthy coping in the context of death.

Gibbons JA, Fehr AM, Brantley JC, Wilson KJ, Lee SA, Walker WR.

Death Stud. 2016 Sep;40(8):513-527. Epub 2016 Jun 3.

PMID:
27261212
18.

Erratum for Stromdahl et al., Borrelia burgdorferi Not Confirmed in Human-Biting Amblyomma americanum Ticks from the Southeastern United States.

Stromdahl EY, Nadolny RM, Gibbons JA, Auckland LD, Vince MA, Elkins CE, Murphy MP, Hickling GJ, Eshoo MW, Carolan HE, Crowder CD, Pilgard MA, Hamer SA.

J Clin Microbiol. 2016 May;54(5):1406. doi: 10.1128/JCM.00527-16. No abstract available.

19.

Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.

Morris MJ, Rathkopf DE, Novotny W, Gibbons JA, Peterson AC, Khondker Z, Ouatas T, Scher HI, Fleming MT.

Clin Cancer Res. 2016 Aug 1;22(15):3774-81. doi: 10.1158/1078-0432.CCR-15-2638. Epub 2016 Feb 8.

20.

Comment on: "Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer".

Gibbons JA.

Clin Pharmacokinet. 2016 Jan;55(1):131-2. doi: 10.1007/s40262-015-0350-7. No abstract available.

21.

The Fading Affect Bias shows healthy coping at the general level, but not the specific level for religious variables across religious and non-religious events.

Gibbons JA, Hartzler JK, Hartzler AW, Lee SA, Walker WR.

Conscious Cogn. 2015 Nov;36:265-76. doi: 10.1016/j.concog.2015.07.004. Epub 2015 Jul 17.

PMID:
26196449
22.
23.

Pharmacokinetic Drug Interaction Studies with Enzalutamide.

Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, Mol R, Mordenti J, Ouatas T.

Clin Pharmacokinet. 2015 Oct;54(10):1057-69. doi: 10.1007/s40262-015-0283-1.

24.

Clinical Pharmacokinetic Studies of Enzalutamide.

Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, de Vries M, Mordenti J.

Clin Pharmacokinet. 2015 Oct;54(10):1043-55. doi: 10.1007/s40262-015-0271-5.

25.

Borrelia burgdorferi not confirmed in human-biting Amblyomma americanum ticks from the southeastern United States.

Stromdahl EY, Nadolny RM, Gibbons JA, Auckland LD, Vince MA, Elkins CE, Murphy MP, Hickling GJ, Eshoo MW, Carolan HE, Crowder CD, Pilgard MA, Hamer SA.

J Clin Microbiol. 2015 May;53(5):1697-704. doi: 10.1128/JCM.03454-14. Epub 2015 Mar 18. Erratum in: J Clin Microbiol. 2016 May;54(5):1406.

26.

Inferior g protection with an electrical muscle stimulation suit compared to a standard g-suit.

Balldin UI, Gibbons JA.

Aviat Space Environ Med. 2014 Nov;85(11):1071-7. doi: 10.3357/ASEM.4082.2014.

PMID:
25329938
27.

Visuo-cognitive skill deficits in Alzheimer's disease and Lewy body disease: A comparative analysis.

Li X, Rastogi P, Gibbons JA, Chaudhury S.

Ann Indian Acad Neurol. 2014 Jan;17(1):12-8. doi: 10.4103/0972-2327.128530. Review.

28.

Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS/MS.

Bennett D, Gibbons JA, Mol R, Ohtsu Y, Williard C.

Bioanalysis. 2014 Mar;6(6):737-44. doi: 10.4155/bio.13.325. Epub 2013 Dec 12.

PMID:
24328824
29.

The fading affect bias across alcohol consumption frequency for alcohol-related and non-alcohol-related events.

Gibbons JA, Toscano A, Kofron S, Rothwell C, Lee SA, Ritchie TD, Walker WR.

Conscious Cogn. 2013 Dec;22(4):1340-51. doi: 10.1016/j.concog.2013.09.004. Epub 2013 Oct 2.

PMID:
24091020
30.

Metabolic regulation of CaMKII protein and caspases in Xenopus laevis egg extracts.

McCoy F, Darbandi R, Chen SI, Eckard L, Dodd K, Jones K, Baucum AJ 2nd, Gibbons JA, Lin SH, Colbran RJ, Nutt LK.

J Biol Chem. 2013 Mar 29;288(13):8838-48. doi: 10.1074/jbc.M112.437186. Epub 2013 Feb 11.

31.

Lactoferrin and cancer in different cancer models.

Gibbons JA, Kanwar RK, Kanwar JR.

Front Biosci (Schol Ed). 2011 Jun 1;3:1080-8. Review.

PMID:
21622257
32.

Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism.

Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, Protter AA.

J Pharmacol Exp Ther. 2010 Jun;333(3):748-57. doi: 10.1124/jpet.109.164491. Epub 2010 Mar 1.

PMID:
20194526
33.

Enhanced cell-associated plasminogen activator pathway but not coagulation pathway activity contributes to motility in metastatic breast cancer cells.

Carter JC, Campbell RA, Gibbons JA, Gramling MW, Wolberg AS, Church FC.

J Thromb Haemost. 2010 Jun;8(6):1323-32. doi: 10.1111/j.1538-7836.2010.03825.x. Epub 2010 Feb 24.

34.

Cross-species comparisons of the pharmacokinetics of ibudilast.

Sanftner LM, Gibbons JA, Gross MI, Suzuki BM, Gaeta FC, Johnson KW.

Xenobiotica. 2009 Dec;39(12):964-77. doi: 10.3109/00498250903254340.

PMID:
19925385
35.

Why people rehearse their memories: frequency of use and relations to the intensity of emotions associated with autobiographical memories.

Walker WR, Skowronski JJ, Gibbons JA, Vogl RJ, Ritchie TD.

Memory. 2009 Oct;17(7):760-73. doi: 10.1080/09658210903107846. Epub 2009 Aug 4.

PMID:
19657960
36.

Metabolic control of oocyte apoptosis mediated by 14-3-3zeta-regulated dephosphorylation of caspase-2.

Nutt LK, Buchakjian MR, Gan E, Darbandi R, Yoon SY, Wu JQ, Miyamoto YJ, Gibbons JA, Andersen JL, Freel CD, Tang W, He C, Kurokawa M, Wang Y, Margolis SS, Fissore RA, Kornbluth S.

Dev Cell. 2009 Jun;16(6):856-66. doi: 10.1016/j.devcel.2009.04.005. Erratum in: Dev Cell. 2010 Jan 19;18(1):165. Gibbon, Jennifer A [corrected to Gibbons, Jennifer A].

37.

Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses.

Rolan P, Gibbons JA, He L, Chang E, Jones D, Gross MI, Davidson JB, Sanftner LM, Johnson KW.

Br J Clin Pharmacol. 2008 Dec;66(6):792-801. doi: 10.1111/j.1365-2125.2008.03270.x.

38.

Acceleration tolerance at night with acute fatigue and stimulants.

Ramsey CS, Werchan PM, Isdahl WM, Fischer J, Gibbons JA.

Aviat Space Environ Med. 2008 Aug;79(8):769-73.

PMID:
18717116
39.
40.

Influence of recall procedures on the modality effect with numbers and enumerated stimuli.

Gibbons JA, Velkey AK, Partin KT.

J Gen Psychol. 2008 Jan;135(1):84-104. doi: 10.3200/GENP.135.1.84-104.

PMID:
18318410
41.

Expression of human protein phosphatase-1 in Saccharomyces cerevisiae highlights the role of phosphatase isoforms in regulating eukaryotic functions.

Gibbons JA, Kozubowski L, Tatchell K, Shenolikar S.

J Biol Chem. 2007 Jul 27;282(30):21838-47. Epub 2007 Jun 1.

42.

Importance of a surface hydrophobic pocket on protein phosphatase-1 catalytic subunit in recognizing cellular regulators.

Gibbons JA, Weiser DC, Shenolikar S.

J Biol Chem. 2005 Apr 22;280(16):15903-11. Epub 2005 Feb 9.

43.

Heterogeneity of toxicant response: sources of human variability.

Aldridge JE, Gibbons JA, Flaherty MM, Kreider ML, Romano JA, Levin ED.

Toxicol Sci. 2003 Nov;76(1):3-20. Epub 2003 Jul 25. Review.

PMID:
12883075
44.

Case history of serious altitude decompression sickness following rapid rate of ascent.

Gibbons JA, Ramsey CS, Wright JK, Pilmanis AA.

Aviat Space Environ Med. 2003 Jun;74(6 Pt 1):675-8.

PMID:
12793542
45.

A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.

Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, Gibbons JA, Cheng SL, Delaria KA, Fleischer R, Greve JM, Gundel R, Harris K, Kelly R, Koh B, Li Y, Lantz L, Mak P, Neyer L, Plym MJ, Roczniak S, Serban D, Thrift J, Tsuchiyama L, Wetzel M, Wong M, Zolotorev A.

Nat Biotechnol. 2000 Nov;18(11):1197-202.

PMID:
11062441
46.

Who's your daddy?: a constitutional analysis of post-mortem insemination.

Gibbons JA.

J Contemp Health Law Policy. 1997 Fall;14(1):187-210. Review. No abstract available.

PMID:
9458614
47.

Intestinal absorption screening of mixtures from combinatorial libraries in the Caco-2 model.

Taylor EW, Gibbons JA, Braeckman RA.

Pharm Res. 1997 May;14(5):572-7.

PMID:
9165526
48.

Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.

Freedman RS, Gibbons JA, Giedlin M, Kudelka AP, Kavanagh JJ, Edwards CL, Carrasco CH, Nash MA, Platsoucas CD.

J Immunother Emphasis Tumor Immunol. 1996 Nov;19(6):443-51.

PMID:
9041464
49.

Pharmacologic characterization of CHIR 2279, an N-substituted glycine peptoid with high-affinity binding for alpha 1-adrenoceptors.

Gibbons JA, Hancock AA, Vitt CR, Knepper S, Buckner SA, Brune ME, Milicic I, Kerwin JF Jr, Richter LS, Taylor EW, Spear KL, Zuckermann RN, Spellmeyer DC, Braeckman RA, Moos WH.

J Pharmacol Exp Ther. 1996 May;277(2):885-99.

PMID:
8627571
50.

Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureter-ligated rats.

Gibbons JA, Luo ZP, Hannon ER, Braeckman RA, Young JD.

J Pharmacol Exp Ther. 1995 Jan;272(1):119-25.

PMID:
7815324

Supplemental Content

Loading ...
Support Center